ALT, AST and GGT was higher in NAFLD patients than in non-NAFLD patients [WMD = 10.21, 95% CI (6.59, 13.83), Z = 5.533, P < 0.001; WMD = 3.95, 95% CI (3.11, 4.78), Z = 9.311, P < 0.001; WMD = 12.88, 95% CI (6.5, 19.26), Z = 3.958, P < 0.001]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.